Nintedanib in children and adolescents with fibrosing interstitial lung diseases

BACKGROUND: Childhood interstitial lung disease (ILD) comprises a spectrum of rare ILDs affecting infants, children and adolescents. Nintedanib is a licensed treatment for pulmonary fibrosis in adults. The primary objectives of the InPedILD trial were to determine the dose-exposure and safety of nin...

Descripción completa

Detalles Bibliográficos
Autores principales: Deterding, Robin, Young, Lisa R., DeBoer, Emily M., Warburton, David, Cunningham, Steven, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Dumistracel, Mihaela, Erhardt, Elvira, Bertulis, Julia, Gahlemann, Martina, Stowasser, Susanne, Griese, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892863/
https://www.ncbi.nlm.nih.gov/pubmed/36041751
http://dx.doi.org/10.1183/13993003.01512-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892863/
https://www.ncbi.nlm.nih.gov/pubmed/36041751
http://dx.doi.org/10.1183/13993003.01512-2022

Ejemplares similares